Research programme: RNA interference-based viral therapeutics - MDRNA

Drug Profile

Research programme: RNA interference-based viral therapeutics - MDRNA

Alternative Names: G 00101; MDR-03030; MDRNA Dicer substrate siRNAs for influenza

Latest Information Update: 24 Aug 2010

Price : $50

At a glance

  • Originator Nastech Pharmaceutical Company
  • Developer Marina Biotech
  • Class Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Influenza virus infections; Metapneumovirus infections

Most Recent Events

  • 22 Jul 2010 Discontinued - Preclinical for Metapneumovirus-infections in USA (unspecified route)
  • 22 Jul 2010 Discontinued - Preclinical for Influenza virus infections in USA (Intranasal)
  • 23 Dec 2009 No development reported - Preclinical for Metapneumovirus-infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top